Information Provided By:
Fly News Breaks for February 21, 2017
GILD, SRPT
Feb 21, 2017 | 09:47 EDT
After Sarepta (SRPT) disclosed it has agreed to sell its pediatric priority review voucher to Gilead (GILD) for $125M, Leerink analyst Joseph Schwartz said that price was below his expectations of $200M and wonders if management could have generated a higher valuation. However, the PRV sale gives Sarepta non-dilutive financing to support its trials and collaborations, added Schwartz, who keeps a Market Perform rating on Sarepta shares.
News For SRPT;GILD From the Last 2 Days
GILD
Apr 22, 2024 | 07:19 EDT
Cantor Fitzgerald lowered the firm's price target on Gilead to $75 from $78 and keeps a Neutral rating on the shares. The firm, which made slight adjustments to all of its large-cap biotechnology models ahead of Q1 earnings season for the group, lowered its target for Gilead given slower expected HIV growth. The "usual seasonal headwinds that typically make this one of the weaker quarters for the industry," the analyst added in the preview note.
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.